New Delhi : Ranbaxy Laboratories declined to comment on reports from Brussels that European Union anti-trust regulators may fine it for allegedly blocking the entry of cheaper generic medicines in the EU. Reports said that Ranbaxy was among the nine companies that are to be fined. When contacted, a Ranbaxy spokesperson said: “We will not like to offer any comments at this point”. Other firms named in the reports were Denmark’s Lundbeck, Merck KGaA, Generics UK, Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma and AL Industriers. Shares of Ranbaxy fell by 3.49% to end at Rs 362.35 apiece at the BSE on Monday.
EU regulators may fine Ranbaxy and other drug makers
RECENT STORIES
Tata Motors Consolidated Revenue Jumps To ₹21,847 Crore In Q3, Net Profit Recovers To ₹705 Crore...
REC Ltd Net Profit Slightly Rises To ₹4,043 Crore In Q3, Revenue At ₹14,911 Crore Amid Marginal...
Sensex Jumps 222 Points, Nifty Tops 25,400 As Economic Survey Fuels Third Straight Market Rally
Skipper Ltd Q3 Profit Jumps 46% YoY To ₹52.8 Crore, Revenue Rises To ₹1,370.6 Crore
Gillette India Q3 Profit Surges 37% To ₹173 Crore, Revenue At ₹790 Crore Despite QoQ Dip